CKD-843 dose#1CKD-843 dose#2Placebo of CKD-843 doseDutasteride Capsules →Placebo of Dutasteride Capsule
CKD-843 dose#1: IM injection every 3 months for 12 months
CKD-843 dose#2: IM injection every 3 months for 12 months
Placebo of CKD-843 dose: IM injection every 3 months for 12 months
Dutasteride Capsules: oral, once daily, 12 months
Placebo of Dutasteride Capsule: oral, once daily, 12 months
Study summary
This is a multi-centers, randomized, double-blind, parallel-group, Phase 3 Trial to evaluate the efficacy and safety of CKD-843 in Male patients with Androgenetic Alopecia
Eligibility
Sex
MALE
Min age
18 Years
Max age
50 Years
Healthy volunteers
No
Key Inclusion Criteria:
* Male of age 18-50 years
* Clinical Diagnosis of Androgenetic Alopecia
* Written informed consent
Key Exclusion Criteria:
* Other types of Alopecia or other diseases that can cause hair loss
* Clinically significant scalp disease such as seborrheic dermatitis or psoriasis
* Clinically significant hepatic disease, thyroid disease, or mental illness, as determined by the Investigator
* Participants who do not agree to use contraception during the trial and for 24 weeks after the last dose, and plan to provide sperm or conceive within 24 weeks after the last dose
Primary outcome measure(s)
Total number of hair Changes — Baseline, Week 24 from Baseline at Week24 of total number of hair changes
Trial sites (1)
Facility
City
Region
Status
Seoul National University Hospital
Seoul
South Korea
Recruiting
More Chong Kun Dang Pharmaceutical trials in South Korea
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.